Table 3. Early treatment effects on CRP.
| Change from baseline to day 56 | Difference from control at day 56 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Unadjusted | Adjusted | ||||||||
| Mean | 95% CI | P | Mean | 95% CI | P | Mean | 95% CI | P | |
| Control | -57.42 | -71.86; -42.98 | <0.0001 | 0 | - | - | 0 | - | - |
| CC-11050 | -62.13 | -81.40; -42.86 | <0.0001 | -5.09 | -28.47; 18.30 | 0.668 | -3.53 | -11.75; 4.69 | 0.398 |
| Everolimus | -44.65 | -69.54; -20.57 | <0.0001 | 12.39 | -11.68; 36.46 | 0.311 | 5.96 | -2.51; 14.42 | 0.167 |
| Auranofin | -73.11 | -94.13; -52.09 | <0.0001 | -16.07 | -39.45; 7.32 | 0.177 | -0.66 | -8.92; 7.59 | 0.874 |
| Ergocalciferol | -73.36 | -94.64; -51.58 | <0.0001 | -16.32 | -39.87; 7.22 | 0.173 | -0.3.21 | -11.52; 5.09 | 0.446 |
In the left panel, differences were determined by paired t test. In the right panel, differences were determined by ANCOVA, before and after adjustment based on differences from control at baseline in CRP. CI = confidence interval.